Abstract
Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovarian cancer on checkpoint inhibitor therapy. We describe 3 hypothetical case vignettes of patients with gynecologic cancer on checkpoint inhibitor immunotherapy and discuss common immune-related adverse events. The typical presentation and onset of immune-related events are different from those associated with conventional chemotherapy. This report highlights the importance of early recognition and management of these events.
Original language | English (US) |
---|---|
Pages (from-to) | 389-394 |
Number of pages | 6 |
Journal | Clinical Therapeutics |
Volume | 40 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2018 |
Keywords
- anti-CTLA-4
- anti-PD1
- hypophysitis
- immune checkpoint inhibitors
- pneumonitis
- thyroiditis
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)